scispace - formally typeset
A

Ali Tofigh

Researcher at McGill University

Publications -  13
Citations -  727

Ali Tofigh is an academic researcher from McGill University. The author has contributed to research in topics: Gene signature & Signal transduction. The author has an hindex of 9, co-authored 13 publications receiving 668 citations. Previous affiliations of Ali Tofigh include Royal Institute of Technology.

Papers
More filters
Journal ArticleDOI

SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor.

TL;DR: IGF-1 promotes the modification of IGF-1R by small ubiquitin-like modifier protein–1 (SUMO-1) and its translocation to the nucleus, demonstrating a SUMOylation-mediated mechanism of IGF -1R signaling that has potential implications for gene regulation.
Journal ArticleDOI

Simultaneous Identification of Duplications and Lateral Gene Transfers

TL;DR: This paper describes a combinatorial model where so-called DTL-scenarios are used to explain the differences between a gene tree and a corresponding species tree taking into account gene duplications, gene losses, and lateral gene transfers (also known as horizontal gene transfers).
Journal ArticleDOI

A Bayesian method for analyzing lateral gene transfer.

TL;DR: A Bayesian Markov-chain Monte Carlo-based method is presented that integrates GD, gene loss, LGT, and sequence evolution, and is applied in a genome-wide analysis of two groups of bacteria: Mollicutes and Cyanobacteria.
Proceedings ArticleDOI

Simultaneous identification of duplications and lateral transfers

TL;DR: This paper introduces a combinatorial model that incorporates duplication events as well as lateral gene transfer events and gives an NP-completeness proof which suggests that the intractability is due to the demand that the dt-scenarios be acyclic.
Journal ArticleDOI

The Prognostic Ease and Difficulty of Invasive Breast Carcinoma

TL;DR: The approach constructively shows how to avoid confounding due to a patient's subtype, clinicopathological profile, or treatment profile and identifies patients who are predicted to have good outcome at time of diagnosis but who experience a distant metastasis within 5 years.